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Standardizing clinical care measures of rheumatic heart disease in 1 
pregnancy: a qualitative synthesis 2 
Abstract 3 
Background: Rheumatic heart disease (RHD) is a preventable cardiac condition that 4 
escalates risk in pregnancy. Models of care informed by evidence-based clinical guidelines 5 
are essential to optimal health outcomes. There are no published reviews that systematically 6 
explore approaches to care provision for pregnant women with RHD and examine reported 7 
measures. The review objective was to improve understanding of reporting of attributes of 8 
care for these women and how they align to guidelines. 9 
Methods: A search of 13 databases was supported by hand-searching. Papers that met 10 
inclusion criteria were appraised using CASP/JBI checklists. 11 
A content analysis of extracted data from the findings sections of included papers was 12 
undertaken, informed by attributes of quality care identified previously from existing 13 
guidelines. 14 
Results: The 43 included studies were predominantly conducted in tertiary care centers of 15 
low-middle-income countries. 16 
Cardiac guidelines were referred to in 25/43 studies. Poorer outcomes were associated with 17 
higher risk scores (detailed in 36/41 quantitative studies). 18 
Indicators associated with increased risk include anticoagulation during pregnancy (28/41 19 
reported) and late booking (gestation documented in 15/41 studies). Limited access to cardiac 20 
interventions was discussed (19/43) in the context of poorer outcomes. Conversely, early 21 
assessment and access to regular multidisciplinary care was emphasized in promoting optimal 22 
outcomes for women and their babies. 23 
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Conclusions: Despite often complex care requirements in challenging environments, 24 
pregnancy provides an opportunity to strengthen health system responses and address whole-25 
of-life health for women with RHD. A standard set of core indicators is proposed to more 26 
accurately benchmark care pathways, outcomes and burden. 27 
Keywords: Health Care Quality, Access, and Evaluation; Pregnancy; Rheumatic Heart 28 
Disease; Social Determinants of Health; Systematic review, Best practice 29 
 30 
Abbreviations: CARPREG CARdiac disease in PREGnancy risk score; NYHA New York 31 
Heart Association functional class (I-IV); CDiP Cardiac disease in pregnancy; RHD 32 
Rheumatic heart disease; RHD-P RHD in pregnancy;  33 
 34 
Key message/Tweetable abstract 35 
Key reporting measures in studies that include rheumatic heart disease in pregnancy are often 36 
poorly recorded. We can do better. A core dataset proposed to more accurately benchmark 37 
care pathways, outcomes and burden of RHD in pregnancy. 38 
  39 
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Standardizing clinical care measures of rheumatic heart disease in 40 
pregnancy: a qualitative synthesis 41 
Introduction 42 
Rheumatic heart disease (RHD) is a preventable disease of inequity. It is twice as common in 43 
women1-4, creating added risk in pregnancy. There are many challenges to providing optimal 44 
care for women with RHD, particularly in low-and-middle income countries. Service 45 
provision is limited by poorly-resourced expertise and facilities with barriers of distance and 46 
cost. There is often deficient awareness for women and health services of RHD and its impact 47 
in pregnancy. 48 
Consequently, the higher prevalence of RHD in pregnancy (RHD-P) in low-and-middle 49 
income countries is matched by poorer outcomes than in high-income countries, with 50 
documented maternal mortality rates of up to 37%5. Its burden is also high among vulnerable 51 
populations in upper-income countries. In Australia, Aboriginal and Torres Strait Islander 52 
women are over five times more likely to die from RHD6, with RHD-P rates for Aboriginal 53 
Northern Territory women up to 63 times those of non-Indigenous women7. Inequitable 54 
outcomes are also seen in Māori and Pasifika women8 and First Nation populations in North 55 
America9,10. There are growing numbers of women with RHD in high-income countries as 56 
migration from resource-poor countries increases11,12. 57 
There are no known systematic reviews that describe approaches to care and associated 58 
reporting measures for women with RHD-P globally. A review of the burden of antenatal 59 
cardiac disease in South Africa has a strong focus on RHD13. Guidelines refer to all-60 
cardiovascular pathologies in pregnancy14, or are referenced in non-pregnancy-specific 61 
cardiac valvular15-17 or RHD-specific guidelines4. 62 
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Reporting measures for studies of cardiac disease in pregnancy are currently in 63 
development18 as part of the Core Outcomes in Women’s and Newborn Health (CROWN) 64 
initiative19,20, but there is no known equivalent for RHD-P, which has specific risks related to 65 
its epidemiology. 66 
While clinical pathways can vary considerably according to the severity of RHD, principles 67 
of care that promote optimal maternal and baby outcomes include early diagnosis; 68 
preconception care including surgery and other interventions where required; early antenatal 69 
assessment including echocardiogram; access to specialized centers and treatment for high-70 
risk women; and collaborative individualized care across disciplines and sectors4,14,21. 71 
The purpose of this study was to systematically examine descriptions of care provision and 72 
associated outcomes for women with RHD-P in order to improve the understanding of how 73 
attributes of care are reported and how they align with guidelines. 74 
Methods 75 
Due to the lack of internationally accepted RHD-P measures we reviewed relevant models of 76 
care and associated reporting measures referred to in clinical guidelines to conceptualize 77 
existing measures in a framework. We found no specific guidelines for RHD-P. Guidelines 78 
were chosen that addressed all-cardiac disease in pregnancy14 and RHD with some reference 79 
to pregnancy4. 80 
The scope was further broadened to include cardiovascular care standards in primary health 81 
settings for Australian Aboriginal and Torres Strait Islander peoples21. This guideline outlines 82 
elements of care across the continuum of risk and disease, with a focus on reducing disparity 83 
in access and outcomes: applicable for most populations where RHD is disproportionate. 84 
Reporting measures relevant for women with RHD-P were identified and grouped in three 85 
categories to provide an analytic tool with which to interrogate the literature (Figure 1). 86 
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These included: clinical information and reporting; risk in pregnancy; and RHD through the 87 
life-course. This framework served to guide the analysis of data gathered for the systematic 88 
review presented in this paper. 89 
Data sources and search protocol 90 
A structured search of peer-reviewed research literature identified studies that described 91 
clinical care and measures for women with RHD-P. Data were extracted from the reported 92 
results of included studies and examined using a content analytic process22, directed by the 93 
framework of reporting measures (Figure 1). 94 
The study was registered with the International Prospective Register of Systematic Reviews 95 
(PROSPERO #CRD42018059849). 96 
Searches on PubMed, Medline, EMBASE, CINAHL, Nursing and Allied Health Database, 97 
ATSIhealth, Indigenous Collection, Rural and Remote Health Database, ETG Complete, ISI 98 
Web of Science, Public Library of Science and Trip Pro Databases; were supported by hand-99 
searching. The search strategy incorporated a combination of free term text items and 100 
Medical Subject Headings (MeSH): ("rheumatic heart" or "rheumatic fever" or “valvular 101 
heart disease”) and ("pregnancy" or "pregnancy complications" or "pregnancy, high-risk" or 102 
"pregnancy complications, cardiovascular" "maternal") and ("models of care" or "guideline*" 103 
or "health service" or "maternal health services" or "primary health care" or "practice 104 
guideline" or "guideline adherence" or "health services accessibility" or "health care"). 105 
Inclusion criteria included: all English-language peer-reviewed studies after 1994 in any 106 
setting or country with reference to RHD-P and attributes of care (Table 1). 107 
The PICOS framework (Population, Interventions, Comparators, Outcomes, Study design)23 108 
guided the review question: In studies that reference pregnant women with RHD, what core 109 
reporting measures are used to describe models of care? 110 
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The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 111 
guidelines24 informed the review. Screening utilized Endnote™ bibliographic and 112 
Covidence™review tools. Critical appraisal referenced CASP and JBI checklists25,26 and the 113 
quality appraisal is summarized in Figure 4 as a four-tier grading. Differing judgments on 114 
inclusion were resolved by consensus, or, where no consensus was achieved, by a third 115 
reviewer. Reasons for excluding studies were clearly documented (Figure 2). 116 
Data extraction and content analysis 117 
A data extraction tool was developed using Microsoft Excel™. Visual mapping used 118 
Tableau™v2018.2.0 analytic software. Study characteristics included (Table 2, Figure 3) 119 
country, World Bank income category, study design, setting/s and population, as well as 120 
documenting maternal mortality. Data were coded against the reporting framework and 121 
associated measures (Figure 1). 122 
Results 123 
General characteristics and quality appraisal 124 
The most common types of study design were cohort (19) and case-series (20), with two 125 
qualitative27,28 studies, one cross-sectional29 and one longitudinal screening study30. There 126 
was considerable heterogeneity in the methodologies, levels of evidence and reporting 127 
measures of these predominantly retrospective studies. Individual study characteristics are 128 
outlined in Table 2. Reflecting the overall burden of RHD, the majority of the 43 studies from 129 
18 countries were from India (8), South Africa (6), Pakistan (4) and Thailand (4), with one 130 
multi-country (predominantly Egypt) study (Figure 3). Most were published after 2004, 131 
paralleling a resurged clinical and research interest31. The distribution of studies by country 132 
and World Bank income category is detailed in Figure 3. 133 
All studies were conducted in tertiary care settings with access to cardiac (or dedicated 134 
obstetric-cardiac) care, as well as primary health settings27,28,30 and regional centers30,32. 135 
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Maternal mortality ranged from 0% (16/42) to 37%5. Between 1-4% of women died in nearly 136 
half (20) of the studies. One study found significantly lower mortality rates in its index 137 
population (10%) compared to referred women (32%)32. 138 
Study designs impacted on quality and were subject to high levels of bias, especially the case 139 
series. Referral and other selection biases as acknowledged in several papers30,32-43 were 140 
particularly related to the predominantly single site tertiary care level settings. 141 
Study periods ranged from six months to 21 years, with five of unspecified periods39,44-47. 142 
Long study periods (from 10-21 years in 16 studies) were noted to impact on protocols which 143 
changed in response to therapeutic advances during that time33. Figure 4 provides the quality 144 
appraisal overview and maps studies against reporting measures. The studies were assessed 145 
as low (9), medium (12), medium-high (21) and high (1) quality respectively. Key reporting 146 
measures from the framework (Figure 1) were poorly documented. 147 
Clinical information reporting 148 
The percentage of the study population with RHD ranged from 100% (11 studies of women 149 
with RHD or mitral stenosis) to 3% in a high-income country11, with most comprising over 150 
55% of the study population (Table 2). Six studies29,46,48-51 from countries with an otherwise 151 
medium-to-high burden of RHD did not give a breakdown of underlying pathology of mitral 152 
stenosis or all-valvular heart disease(Table 2, Figure 4). Mitral stenosis in women during 153 
their reproductive years is usually of rheumatic origin14,52 and was used as a proxy for RHD 154 
where causation was unspecified. 155 
Heart disease in low-and-middle income countries is commonly diagnosed in pregnancy on 156 
development of severe symptoms5,13,32,44,53. However, 18 of the 41 quantitative studies did not 157 
specify timing of diagnosis. Others referred to late diagnosis in the context of poorer 158 
outcomes and health system shortcomings35,40,41,49,51,54-56. Diagnosis during pregnancy/post-159 
partum ranged from 1%57 to 97%30 in a longitudinal screening study, with eight studies above 160 
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20% and four above 40%. In one high-income country, four women (of 95 pregnancies) were 161 
diagnosed with RHD after developing peripartum acute pulmonary oedema58. One found 7% 162 
of women diagnosed post-partum39, but this was poorly documented overall. 163 
Thirty-six studies specified echocardiographic review during pregnancy, although only four 164 
referenced diagnostic criteria30,43,48,58. Six studies did not specify RHD diagnosis confirmed 165 
by echocardiography, nor its use during pregnancy5,46,53,59-61. 166 
Models of care and risk in pregnancy 167 
There was limited or no reference made to guidelines related to the care of pregnant women 168 
with cardiac disease in 16 studies. 169 
The majority of the 36 quantitative studies that specified a cardiac risk score used the New 170 
York Heart Association (NYHA)  classification (I-IV) of functional capacity62. Pregnancy-171 
specific scores referenced CARdiac disease in PREGnancy (CARPREG)63 cardiac events risk 172 
index, modified CARPREG58, and modified World Health Organisation (mWHO) risk 173 
classifications14,64. A referral algorithm was developed for suspected and known 174 
cardiovascular disease in a low-resource setting40.  175 
Poorer maternal and fetal outcomes were associated with higher risk scores 176 
(NYHA>II29,35,38,42,43,45-47,50,53-57,59,60,65-71, NYHA>I with mitral stenosis43, mWHO>140, 177 
CARPREG36,54,67,72/modified CARPREG58>0 or study-specific factors such as mitral stenosis 178 
and anticoagulation therapy leading to increased maternal risks of heart failure, pulmonary 179 
hypertension, thromboembolic episodes, atrial fibrillation and death30,32,37,41,46,48,49,51). The 180 
CARPREG index underestimated cardiac events in low-risk women but over-estimated it in 181 
CARPREG>0 in one study, possibly reflecting late diagnoses in pregnancy54. The quality of 182 
care and avoidable factors associated with near-miss morbidity was assessed in two 183 
papers32,41, while others described gaps between guideline recommendations and clinical 184 
implementation leading to compromised care11,43. 185 
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Late booking and/or infrequent antenatal care hampered early diagnosis and 186 
treatment5,49,59and was associated with poorer cardiac and perinatal 187 
outcomes32,40,41,49,51,67,69,70, yet the gestational age at first antenatal visit was reported in only 188 
15 of 41 quantitative studies. 189 
Medical management (such as beta-blockers, digoxin and/or diuretics) and Percutaneous 190 
Balloon Mitral Valvuloplasty73 (PBMV, hereafter valvuloplasty) in refractory cases of mitral 191 
stenosis generally improved outcomes33,34,56 where reported. However, studies emphasized 192 
the challenges of providing optimal care in resource-challenged environments, including 193 
appropriate clinician skills, access to medication, valvuloplasty and surgery, health system 194 
shortcomings and sociocultural factors27,30,32,34,35,40,41,43,44,46,49,51,54-56,59, with one (where 37% 195 
of women with rheumatic valvular disease died) noting that valvuloplasty facilities were 196 
simply unavailable at their tertiary center5. The multi-country study found a greater number 197 
of valvular interventions in high-income countries despite more women in low-income 198 
settings having severe mitral stenosis43. 199 
Despite the potentially catastrophic maternal-fetal risks associated with the use of 200 
anticoagulation in pregnancy, the regimen was detailed in only half of the 28 quantitative 201 
studies that specified the number of women on therapy. Nine referred to discussion with 202 
women in the context of complex decisions surrounding choice of regimen which balanced 203 
the maternal risk of thromboembolism using low molecular weight heparin against the 204 
increased fetal risk of warfarin use. Studies discussed late booking affecting the 205 
anticoagulation regimen47,51,66,70 with lack of adherence to protocol (or access to treatment) 206 
detailed as an important risk factor for morbidity and mortality41,47,51,53,57. Warfarin 207 
embryopathy/fetopathy was likely underestimated in studies where postmortems or detailed 208 
examinations were not performed41,65. 209 
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Secondary prophylaxis (usually 3-4 weekly bicillin injections), where indicated, prevents 210 
rheumatic fever recurrence and is safe during pregnancy. Its use was referred to in only seven 211 
quantitative studies. 212 
Most studies emphasized the need for multidisciplinary care in discussion and/or 213 
recommendations although somewhat fewer (32) specified its provision in their study. This 214 
was highlighted in one study that found obstetric-cardiac individualized review determined 215 
according to risk promoted optimal outcomes despite its low-resource setting40. Others 216 
similarly pointed to early multidisciplinary evaluation and management contributing to few 217 
or no maternal deaths in otherwise high-risk women38,47,49,50,56,58,61,65,68,70,71. 218 
Vaginal birth is recommended for women with valvular heart disease unless contraindicated 219 
by severe cardiac morbidity14, or obstetric complications. Caesarean section rates varied 220 
enormously from less than 10%44,46,50,61 to 75%69, with several studies above 40%35,41-221 
43,47,57,68 and higher again in groups stratified by risk or poorer outcomes42,43,57,68,69. 222 
There was limited reference to care outside the index pregnancy period. Those that did noted 223 
the continued heightened risk of morbidity and mortality40,43, and another detailed an 224 
increased need for cardiac intervention in the first year following delivery11. 225 
Papers that called for improved clinician training in primary health settings to support cardiac 226 
disease detection/referral48,51,67 were mostly (5/6) published since 2014. Gaps in awareness 227 
among primary health care nurses (and women) were associated with delayed referrals40 and 228 
consistent with other studies that found women received contradictory advice and limited 229 
education27,28. Language-appropriate health education that promoted a shared understanding 230 
was largely absent for Aboriginal women with RHD28. 231 
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RHD through the life-course 232 
Twenty-six studies did not specify the provision of conception counselling and reproductive 233 
health in their setting, with one listing it under management standards not followed11. Women 234 
can perceive risk to be over with the end of pregnancy65, underscoring the significance of 235 
postnatal counselling. 236 
Emerging themes in a qualitative study of women’s experiences with RHD included 237 
misconceptions about side-effects of contraceptives; lack of agency in reproductive decision-238 
making; and stigma related to financial and perceived reproductive limitations27. 239 
Discussion 240 
The aim of this review was to synthesize the literature and map reported measures against a 241 
framework drawn from guidelines related to models of care for RHD-P. Our study found 242 
gaps in the three framework categories of clinical reporting, risk in pregnancy and RHD 243 
through the life-course. 244 
A recent overview of RHD strategies emphasizes the imperative for accurate, current data in 245 
order to inform policy and measure trends1. Poor reporting of measures related to cardiac 246 
pathology and diagnoses precludes a true assessment of the burden of RHD-P and changing 247 
epidemiology. In turn, this is limited by the capacity of health services to diagnose cases. 248 
Women with subclinical or milder forms of disease or fatal events prior to admission are 249 
likely to be missed in low-income settings40. The community-based screening study found 250 
less than four percent of women with RHD were aware of their diagnosis pre-pregnancy30. 251 
There are no known studies of the impact of RHD-P from countries that have among the 252 
highest reported rates of RHD in the world74, including the Pacifica75,76 and Oceanic 253 
regions77. A population-based study conducted in the high-income countries of Australia and 254 
New Zealand (currently under review) shows similarly high rates among Māori and Pasifika 255 
women8,78. 256 
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Reporting gaps are consistent with a South African systematic review of antenatal heart 257 
disease, which recommended minimum criteria including diagnosis, reference population, 258 
cardiac profile and outcomes13.  259 
While the lack of diagnostic reference to echocardiography is partly explained by study 260 
periods, resource limitations of facilities and expertise no doubt also impact. However, 261 
increasingly portable technologies and successful screening programs strengthen the 262 
argument for earlier review in primary care settings30,79,80. Standardization has improved with 263 
the 2012 echocardiographic diagnostic criteria81. 264 
The high risk of anticoagulation in pregnancy requires better reporting in any study of women 265 
with RHD. A recent meta-analysis of anticoagulation in women with mechanical heart valves 266 
found fetal risk was similar between women taking <5 mg warfarin daily to those on low-267 
molecular weight heparin82. These findings underscore the need for granularity of reporting 268 
prescribed regimens – including level of adherence and whether women had access to 269 
treatment. 270 
Increasing calls to improve the scale-up of and access to surgery/interventions in low-income 271 
countries83,84 reflect service deficiencies highlighted in studies. 272 
There were few studies that followed RHD-P care trajectories and outcomes outside tertiary 273 
centers. A small but growing number of initiatives such as the landmark RHD screening 274 
study30 harness specialist resources in community settings to improve early diagnosis of RHD 275 
and care for women. These are embedded in collaborative cross-sectoral approaches80, 276 
drawing on successful strategies developed in other chronic disease models and supported by 277 
strengthened health systems30,85. They potentially obviate the need for emergency-driven, 278 
costly tertiary care32 - and in turn support improved outcomes for this disease which is 279 
preventable at many levels.4 Such principles can equally apply to vulnerable populations in 280 
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high-income countries86. However, executing these models in practice is often tested by the 281 
plethora of structural, political and economic barriers to implementation that are part of the 282 
RHD landscape. 283 
The overall lack of reference to post-discharge care (including recommended follow-up) 284 
suggests likely under-reporting of complications. Three of four RHD-related maternal deaths 285 
reported in the multi-country study were up to six months’ post-partum43, consistent with 286 
(often-avoidable) factors and risks reported in other studies of late maternal death87-89. 287 
Existing literature on preconception and reproductive health care is predominantly focused on 288 
congenital heart disease. There is a growing body of evidence of the role of preconception 289 
care in optimizing general health and risk awareness in marginalized communities90: highly 290 
relevant for women with RHD3. 291 
There are no RHD-P-specific guidelines. Selected reporting measures were drawn from 292 
cardiac disease in pregnancy guidelines that referenced RHD14, the Australia-specific RHD 293 
guidelines4,91 (an updated edition of which includes a substantially enhanced section on 294 
women and RHD91) and cardiovascular standards for Aboriginal and Torres Strait Islander 295 
peoples21. Guidelines are themselves mostly based on case series and observational studies. 296 
However, we believe the included reporting measures reflect fundamental principles of care 297 
for vulnerable populations where RHD is prevalent, particularly in relation to maternal 298 
health. RHD-specific research to test the evidence is required to strengthen the rigour of 299 
recommendations, better understand the effects of pregnancy and choose the best 300 
individualized plan for ongoing care. 301 
We propose the reviewed framework of measures (Figure 1) addressing the categories of 302 
clinical information reporting; models of care and risk in pregnancy; and RHD through the 303 
life course as a core outcome set for women with RHD-P, adapted to local cultural, social and 304 
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economic contexts92. A Delphi method review93,94 to evaluate an extended set with neonatal 305 
outcomes (with global stakeholders including health services and women in high-prevalence 306 
settings) will further strengthen recommendations for adoption. 307 
Strengths and limitations 308 
This review was constrained by the heterogeneity and design of included studies, with most 309 
subject to substantial bias (particularly referral) and reporting inconsistencies. Study sites 310 
were predominantly tertiary centers, providing care particularly for those with severe RHD 311 
who were able to access specialist care. However, these observational studies provide the best 312 
available current evidence and insight in determining models of care associated with optimal 313 
maternal outcomes. 314 
What was reported (or not) may not reflect actual practice. In the absence of specific 315 
reference to a care attribute, it was assumed that it was not addressed, which may or may not 316 
be true. This may be particularly relevant for aspects such as conception counselling11. 317 
Conclusions 318 
RHD has been described as providing a model for strengthening health systems to address 319 
other cardiovascular diseases in limited-resource countries. This framework is especially 320 
pertinent for women with RHD, where best-practice models of care in a strengthened 321 
maternal health system are often congruent with those that support women with RHD. 322 
This qualitative synthesis highlights gaps of what is reported in the literature, with 323 
consequent under-estimation of burden and weakened ability to action strategies based on 324 
findings. We propose a Delphi testing of the reporting framework detailed in this paper and 325 
adoption of a core outcome set to support data consistency, comparability of studies, 326 
strengthen knowledge and awareness of burden (clinical and social) and improve 327 
benchmarking of care for women with RHD. 328 
  329 
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English language Non-English 
Any setting in any country None 
Any study of women with cardiac disease 
with reference to RHD and pregnancy 





Studies of biomedical treatments/interventions for 
women with RHD that do not refer to models of 
care in pregnancy 
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Table 2: Characteristics of studies with reference to RHD-P 588 
Legend:  589 
TCC: Tertiary care center; CR: Community setting and/or regional center 590 
PCS: Prospective case-series; RCS: Retrospective case-series; PC: Prospective cohort; RC: Retrospective cohort; PLS: 591 
Prospective longitudinal screening 592 
CDM: Dedicated Cardiac/Maternity clinic; HRPC: High-risk multidisciplinary pregnancy clinic 593 
CDiP: Cardiac disease in pregnancy; VHD: valvular heart disease; MVHD: mitral valvular heart disease; MS: mitral stenosis 594 
Maternal mortality: * Asterisked percentages indicate RHD only 595 
 Study Setting / 
Type of 
care 
Study population Study 
design 






1  Abdel-Hady(2005)57 TCC-HRPC n=86 
RHD=90% 
PCS Egypt Assess maternal/perinatal CDiP 
outcome. 
1%* 
2  Ahmed(2015)48 TCC-HRPC n=101 
RHD=N/S 
MS=100% 




3  Asghar(2005)44 TCC-HRPC n=50 
RHD=66% 
PCS Pakistan Assess maternal/fetal outcome 
CDiP. 
0%* 
4  Avila(2003)33 TCC-HRPC n=1000 
RHD=56% 
RCS Brazil Experiences & outcomes CDiP in 
referral center. 
2% 
5  Barbosa(2000)34 TCC-CDM n=45 
RHD=100% 
RC Brazil Identify characteristics of 
complications MS in pregnancy. 
2%* 
6  Beaton (2018) PLS, CR n=58 
RHD=88% 
PLS Uganda Determine prevalence of maternal 
heart disease through active case 
finding & its attributable risk to 
adverse pregnancy outcomes. 
2%* 











8  Bhatla(2003)56 TCC-HRPC n=207 
RHD=88% 
RC India Evaluate CDiP maternal/fetal 
outcome in developing country. 
0% 
9  Bhutta(2003)65 TCC-HRPC n=170 
RHD=91% 
PCS Pakistan Determine CDiP outcomes post-
cardiac surgery. 
0% 
10  Chang(2018)27 TCC n=50 
n= 25 




Uganda Understand factors/attitudes 
towards reproductive health & 
disease in women with RHD. 
N/A 
(none) 
11  Chhetri(2014)35 TCC-HRPC n=53 
RHD=89% 
PCS Nepal Investigate prevalence, 
characteristics, outcomes CDiP. 
4%* 
12  Chumpathong(2014)36 TCC-HRPC n=175 
RHD=66% 




13  Curtis(2009)11 TCC-HRPC n=177 
RHD=3% 
RCS UK Describe CDiP; review guidelines 
adherence, identify suboptimal 
management. 
2% 
14  Desai(2000)49 TCC-HRPC n=208 
RHD=N/S 
MS=100% 
PCS South Africa Evaluate management/outcomes 
MS in pregnancy. 
0% 
15  Diao(2011)5 TCC-HRPC n=50 
RHD=92% 
RCS Senegal CDiP maternal/foetal outcomes in a 
low-income country. 
37%* 
16  Faiz(2003)50 TCC-HRPC n=126 
RHD=N/S 
MVHD=95% 
RCS Saudi Arabia Review MVHD during pregnancy: 
incidence, outcome. 
0% 
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 Study Setting / 
Type of 
care 
Study population Study 
design 






17  Fu(2015)37 TCC CDM n=1086 RHD=15% RC China Identify heart failure risk during 
pregnancy women with pre-
existing disease 
1%* 
18  Jatavan(2011)59 TCC-HRPC n=125 
RHD=49% 
RC Thailand Determine outcomes CDiP. 0% 
19  Kaluarachchi(1995)66 TCC-HRPC n=166 
RHD=70% 
PCS Sri Lanka Evaluate CDiP pattern and 
outcome. 
2% 
20  Kanwar(2018)67 TCC-HRPC n=66  
RHD=77% 
PC India Identify feto-maternal CDiP 
predictors complications/ 
outcomes ≤28v>28 weeks. 
6% 
21  Konar(2012)45 TCC-HRPC n=281 
RHD=69% 
PCS India Evaluate CDiP, maternal/perinatal 
outcome. 
1% 
22  Kovavisarach(2007)60 TCC-HRPC n=196 
RHD=55% (period 
3) 
RC Thailand Assess prevalence, demographics, 
maternal/perinatal outcomes CDiP 
(3 study periods). 
3% 
23  Madazli(2010)68 TCC-HRPC n=144 
RHD=87% 
RC Turkey Evaluate maternal/fetal outcome 
CDiP developing country. 
0% 
24  Malhotra(2004)46 TCC-HRPC n=312 
RHD=N/S 
VHD=100% 
RC India Compare pregnancy outcomes of 
women with VHD to healthy 
women. 
0.6% 
25  Martins(2016)54 TCC-HRPC n=132 
RHD=62% 
RC Brazil Determine CDiP risk factors 







PC Israel Assess CDiP outcome. 0% 
27  Nqayana(2008)47 TCC CDM n=95 
RHD=81% 
RCS South Africa Review CDiP in developing country. 0% 
28  Pratibha (2014)53 TCC-HRPC n=200 
RHD=100% 
RCS India Study pregnancy outcomes of RHD-
P; evaluate perinatal outcomes of 
Percutaneous Balloon Mitral 
Valvuloplasty during pregnancy. 
1%* 
29  Puri(2013)39 TCC-HRPC n=97 
RHD=70% 
RC India Assess CDiP & associated 
maternal/fetal complications. 
3% 
30  Rahman(2000)61 TCC-HRPC n=274 
RHD=76% 
RCS Saudi Arabia Review CDiP outcomes. 0% 
31  Rezk(2018)69 TCC-HRPC n=204 
RHD=100% 
PC Egypt Assess cardiac/obstetric outcome 
in RHD-P & predictors of poor 
outcome. 
0%* 
32  Sartain(2012)58 TCC-HRPC n=95 
RHD=100% 
RC Australia Determine maternal-cardiac 
complications/outcomes in 
patients with RHD. 
0%* 
33  Sawhney(2003)55 TCC CDM n=500 
RHD=100% 
RC India Study maternal/perinatal outcomes 
RHD-P. 
2% 
34  Schoon(2001)32 TCC-HRPC n=42index+25 
referred 
RHD=33% 
RCS South Africa Document CDiP 
mortality/morbidity; compare 
complicated vs uncomplicated. 
18% 
35  Schoon(1997)51 TCC/regio
nal-HRPC 
n=164 RHD=N/S RCS South Africa Describe maternal outcome CDiP. 10% 




PC Canada Define predictors maternal-cardiac 
complications in women with MS. 
0%* 
37  Sliwa(2014)40 TCC-CDM n=225 
RHD=25% 
PC South Africa Investigate spectrum of disease & 
maternal/fetal outcome in CDM. 
4% 
 page 25 
 Study Setting / 
Type of 
care 
Study population Study 
design 






38  Soma-Pillay(2008)41 TCC-CDM n=189 
RHD=64% 
RCS South Africa Assess CDiP profile & 
maternal/fetal outcome, identify 
risk categories. 
3% 
39  Stangl(2008)42 TCC-HRPC n=93 
RHD=7.5% 
RC Germany Analyze risks in low/high-risk 
women with CDiP. 
0%* 
40  Subbaiah(2013)70 TCC-HRPC n=100 
RHD=64% 







RCS Thailand Identify complications CDiP. 1% 








Assess maternal/fetal outcomes in 
women with MVHD. 
1%* 
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Figure 1: Framework of reporting measures for women with RHD-P 600 
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Figure 2: PRISMA diagram of studies with reference to RHD-P 603 
 604 
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Figure 3: Number of studies referencing women with RHD-P:  609 
by country and World Bank income category 610 
 611 
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Figure 4: Studies with reference to RHD-P:  614 
core reporting measures and quality appraisal by study 615 
Legend: visual representation of specified reporting measures (outlined in figure 1 616 
framework) according to study. Shaded square indicates the reporting measure was specified 617 
in the study; blank square indicates it was not. 618 
Quality appraisal assessed as L (Low), M (Medium), M-H (Medium-high) or H (High).  619 
 620 
 621 
  622 
